These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 21064013)
1. [Novel anticoagulants for stroke prevention in atrial fibrillation]. Baumhäkel M; Schirmer SH; Böhm M Dtsch Med Wochenschr; 2010 Nov; 135(46):2304-8. PubMed ID: 21064013 [TBL] [Abstract][Full Text] [Related]
2. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583 [TBL] [Abstract][Full Text] [Related]
3. Novel oral anticoagulants in secondary prevention of stroke. Diener HC; Easton JD; Hankey GJ; Hart RG Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901 [TBL] [Abstract][Full Text] [Related]
4. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. Lip GY; Larsen TB; Skjøth F; Rasmussen LH J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324 [TBL] [Abstract][Full Text] [Related]
5. Novel oral anticoagulants in non-valvular atrial fibrillation. Potpara TS; Lip GY Best Pract Res Clin Haematol; 2013 Jun; 26(2):115-29. PubMed ID: 23953900 [TBL] [Abstract][Full Text] [Related]
6. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Mantha S; Ansell J Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145 [TBL] [Abstract][Full Text] [Related]
7. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future]. Dumont B; Faille D; Ajzenberg N Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670 [TBL] [Abstract][Full Text] [Related]
8. Antithrombotic treatment of atrial fibrillation: new insights. Le Heuzey JY Thromb Res; 2012 Oct; 130 Suppl 1():S59-60. PubMed ID: 23026665 [TBL] [Abstract][Full Text] [Related]
9. Apixaban for the prevention of stroke in atrial fibrillation. Littrell R; Flaker G Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):143-9. PubMed ID: 22292869 [TBL] [Abstract][Full Text] [Related]
10. Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease. Morales-Vidal S; Schneck MJ; Flaster M; Biller J Expert Rev Neurother; 2012 Feb; 12(2):179-89; quiz 190. PubMed ID: 22288673 [TBL] [Abstract][Full Text] [Related]
11. [Current and future therapies for prophylaxis of thromboembolism in atrial fibrillation]. Geisler T; Gawaz M MMW Fortschr Med; 2011 Apr; 153(15):27-30; quiz 31. PubMed ID: 21667556 [No Abstract] [Full Text] [Related]
12. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Ahrens I; Lip GY; Peter K Thromb Haemost; 2011 Apr; 105(4):574-8. PubMed ID: 21225102 [No Abstract] [Full Text] [Related]
13. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation. Berman JP; Halperin JL Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966 [TBL] [Abstract][Full Text] [Related]
14. A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice. Kasmeridis C; Lip GY; Apostolakis S Hosp Pract (1995); 2013 Feb; 41(1):61-70. PubMed ID: 23466968 [TBL] [Abstract][Full Text] [Related]
15. Stroke prevention in patients with atrial fibrillation: focus on new oral anticoagulants. Toth PP Postgrad Med; 2013 May; 125(3):155-61. PubMed ID: 23748516 [TBL] [Abstract][Full Text] [Related]
16. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era. Contractor T; Levin V; Martinez MW; Marchlinski FE Postgrad Med; 2013 Jan; 125(1):34-44. PubMed ID: 23391669 [TBL] [Abstract][Full Text] [Related]
17. New oral anticoagulants in elderly patients. Barco S; Cheung YW; Eikelboom JW; Coppens M Best Pract Res Clin Haematol; 2013 Jun; 26(2):215-24. PubMed ID: 23953909 [TBL] [Abstract][Full Text] [Related]
18. Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation. Galanis T; Merli GJ Hosp Pract (1995); 2013 Feb; 41(1):26-36. PubMed ID: 23466965 [TBL] [Abstract][Full Text] [Related]
19. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban. Morell J; Sullivan B; Khalabuda M; McBride BF J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518 [TBL] [Abstract][Full Text] [Related]
20. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Harenberg J; Wehling M Semin Thromb Hemost; 2008 Feb; 34(1):39-57. PubMed ID: 18393142 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]